Reviewer's report
Title:Dose-dependent effects of lesogaberan on reflux measures in patients with
refractory gastroesophageal reflux disease: a randomized, placebo-controlled
study
Version:2Date:12 April 2014
Reviewer: Nicola de Bortoli
Reviewer's report:
Dear Authors
I red interestingly the paper titled 'Dose-dependent effects of lesogaberan on
reflux measures in patients with refractory gastroesophageal reflux disease: a
randomized, placebo-controlled study '. This study aimed to explore the
dose–response effect of lesogaberan on reflux episodes in partial responders.
The sample size is rather small but results are quite interesting.
Lesogaberan was discontinued (phase 2 - study of Shaheen
et al. 2013), because its impact on reflux symptoms above placebo was
marginal in patients with an incompete response to PPI treatment.
This paper is well performed, analysed and written so I have no questions for the
aurthors.
I consider this study suitable for pubblication in your journal.
Kind regards.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
None
Reviewer's report
Title:Dose-dependent effects of lesogaberan on reflux measures in patients with
refractory gastroesophageal reflux disease: a randomized, placebo-controlled
study
Version:2Date:12 April 2014
Reviewer: Nicola de Bortoli
Reviewer's report:
Dear Authors
I red interestingly the paper titled 'Dose-dependent effects of lesogaberan on
reflux measures in patients with refractory gastroesophageal reflux disease: a
randomized, placebo-controlled study '. This study aimed to explore the
dose–response effect of lesogaberan on reflux episodes in partial responders.
The sample size is rather small but results are quite interesting.
Lesogaberan was discontinued (phase 2 - study of Shaheen
et al. 2013), because its impact on reflux symptoms above placebo was
marginal in patients with an incompete response to PPI treatment.
This paper is well performed, analysed and written so I have no questions for the
aurthors.
I consider this study suitable for pubblication in your journal.
Kind regards.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
None
Please review this paper.
user
Reviewer's report
Title:Dose-dependent effects of lesogaberan on reflux measures in patients with
refractory gastroesophageal reflux disease: a randomized, placebo-controlled
study
Version:2Date:12 April 2014
Reviewer: Nicola de Bortoli
Reviewer's report:
Dear Authors
I red interestingly the paper titled 'Dose-dependent effects of lesogaberan on
reflux measures in patients with refractory gastroesophageal reflux disease: a
randomized, placebo-controlled study '. This study aimed to explore the
dose–response effect of lesogaberan on reflux episodes in partial responders.
The sample size is rather small but results are quite interesting.
Lesogaberan was discontinued (phase 2 - study of Shaheen
et al. 2013), because its impact on reflux symptoms above placebo was
marginal in patients with an incompete response to PPI treatment.
This paper is well performed, analysed and written so I have no questions for the
aurthors.
I consider this study suitable for pubblication in your journal.
Kind regards.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
None
assistant